Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$69.02 - $93.84 $186,354 - $253,368
-2,700 Reduced 9.0%
27,300 $1.92 Million
Q2 2024

Aug 12, 2024

BUY
$74.43 - $92.22 $2.23 Million - $2.77 Million
30,000 New
30,000 $2.47 Million
Q3 2023

Nov 09, 2023

SELL
$85.07 - $94.48 $2.7 Million - $3 Million
-31,700 Reduced 49.38%
32,500 $2.88 Million
Q2 2023

Aug 10, 2023

SELL
$86.68 - $100.3 $6.14 Million - $7.1 Million
-70,800 Reduced 52.44%
64,200 $5.56 Million
Q1 2023

May 11, 2023

BUY
$87.74 - $117.27 $4.54 Million - $6.06 Million
51,700 Added 62.06%
135,000 $13.1 Million
Q4 2022

Feb 09, 2023

BUY
$80.93 - $108.63 $3.91 Million - $5.25 Million
48,300 Added 138.0%
83,300 $8.62 Million
Q3 2022

Nov 10, 2022

BUY
$82.16 - $96.94 $2.88 Million - $3.39 Million
35,000 New
35,000 $2.97 Million
Q1 2022

May 12, 2022

SELL
$74.28 - $92.69 $14.9 Million - $18.6 Million
-200,200 Reduced 85.19%
34,800 $2.68 Million
Q4 2021

Feb 10, 2022

BUY
$71.72 - $91.47 $16.9 Million - $21.5 Million
235,000 New
235,000 $20.8 Million

Others Institutions Holding BMRN

About BIOMARIN PHARMACEUTICAL INC


  • Ticker BMRN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,824,000
  • Market Cap $12.3B
  • Description
  • BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...
More about BMRN
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.